Applied DNA Sciences Files 8-K for Other Event

TL;DR

APDN filed an 8-K for an 'Other Event' on June 18th. Details TBD.

AI Summary

On June 18, 2024, Applied DNA Sciences, Inc. filed an 8-K report detailing an "Other Event." The filing does not specify the exact nature of the event or any associated financial figures, but it indicates a significant corporate update was made on this date.

Why It Matters

This filing signals a material event has occurred for Applied DNA Sciences, Inc., requiring disclosure to investors and the public.

Risk Assessment

Risk Level: medium — The lack of specific details in this 8-K filing creates uncertainty for investors regarding the nature and impact of the reported event.

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• June 18, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
• $175,385 — March 31, 2024 stockholders' equity of ($175,385), and, as a result, fell below the mini
• $2,500,000 — mum stockholders' equity requirement of $2,500,000 (the "Stockholders' Equity Requirement"
• $10.8 million — nts. The Company received approximately $10.8 million in net proceeds from the Offering after

Filing Documents

• tm2417556d1_8k.htm (8-K) — 25KB
• 0001104659-24-072876.txt ( ) — 192KB
• apdn-20240618.xsd (EX-101.SCH) — 3KB
• apdn-20240618_lab.xml (EX-101.LAB) — 33KB
• apdn-20240618_pre.xml (EX-101.PRE) — 22KB
• tm2417556d1_8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. As previously disclosed on its current report on Form 8-K filed on May 16, 2024, Applied DNA Sciences, Inc. (the "Company") received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq's Listing Rule 5550(b)(1) because the Company reported in its Form 10-Q for the quarter ended March 31, 2024 stockholders' equity of ($175,385), and, as a result, fell below the minimum stockholders' equity requirement of $2,500,000 (the "Stockholders' Equity Requirement"). The notification had no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. In accordance with Nasdaq rules, the Company has been provided 45 calendar days, or until July 1, 2024, to submit a plan to regain compliance with the listing rules for the Nasdaq Capital Market. As previously disclosed in its current report on Form 8-K filed on May 29, 2024, the Company closed on such date a public offering of common stock and warrants (the "Offering") with Craig-Hallum Capital Group LLC and Laidlaw & Company (UK) Ltd. as placement agents. The Company received approximately $10.8 million in net proceeds from the Offering after deducting placement agent fees and other estimated offering expenses payable by the Company. As a result of the Offering, the Company believes it has regained compliance with Nasdaq Listing Rule 5550(b)(1). The Company understands that Nasdaq will continue to monitor the Company's ongoing compliance with the Stockholders' Equity Requirement. If, at the time of its next periodic report, the Company does not evidence compliance with the Stockholders' Equity Requirement, the Company may be subject to delisting.

Financial Statements and Exhibits

Financial Statements and Exhibits. ( d) Exhibits 104 Cover Page Interactive Data File (formatted in Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 18, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR